07:00 , Aug 24, 2015 |  BC Week In Review  |  Company News

Bio-Reference Laboratories, Opko deal

Opko completed its acquisition of clinical service laboratory Bio-Reference. Bio-Reference shareholders received 2.8 shares of Opko stock for each Bio-Reference share held. Based on Opko’s close of $12.63 on Aug. 19, before the deal’s close...
07:00 , Jul 27, 2015 |  BC Week In Review  |  Company News

Bio-Reference Laboratories, Opko deal

Opko will acquire clinical service laboratory Bio-Reference for $1.5 billion in shares. Bio-Reference shareholders will receive 2.8 shares of Opko stock for each Bio-Reference share held. The implied value of $52.58 is a 60% premium...
08:00 , Mar 2, 2015 |  BC Week In Review  |  Company News

Bio-Reference Laboratories, Myriad Genetics diagnostic news

Myriad and Bio-Reference’s GeneDx Inc. subsidiary reached a settlement to dismiss patent litigation related to the breast cancer 1 early onset (BRCA1) and BRCA2 genes. Myriad promised not to sue GeneDx under the patents asserted...
07:00 , Sep 2, 2013 |  BC Week In Review  |  Company News

Bio-Reference Laboratories sales and marketing update

Bio-Reference's GeneDX Inc. subsidiary launched its suite of genetic tests for inherited cancers, including tests for the breast cancer 1 early onset (BRCA1) and BRCA2 genes. Bio-Reference declined to disclose the price. GeneDX said the...
07:00 , Jun 17, 2013 |  BC Week In Review  |  Company News

Bio-Reference Laboratories sales and marketing update

Bio-Reference's GeneDX Inc. subsidiary said it will launch genetic tests as early as Aug. 1 for inherited cancers, including tests for the breast cancer 1 early onset (BRCA1) and BRCA2 genes. Bio-Reference declined to disclose...
07:00 , Jun 17, 2013 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 6/14 cls Addex Therapeutics Ltd. (SIX:ADXN) Wedbush Christopher Marai Downgrade Neutral (from outperform) 18% CHF3.98 Marai also lowered his target to CHF5 from CHF28...
07:00 , Jun 17, 2013 |  BioCentury  |  Finance

Breaching Myriad's walls

Breaching Myriad's walls Myriad Genetics Inc. (NASDAQ:MYGN) jumped more than 10% in intraday trading Thursday as the company claimed victory on a U.S. Supreme Court ruling allowing cDNA patents. But the shares ended the day...
07:00 , May 13, 2013 |  BioCentury  |  Finance

Dx-ing Dx investing

Despite decisions by firms like Atlas Venture and Mohr Davidow to exit the early stage diagnostic space, other VCs believe the evolution of underlying technologies and the long-term need to control healthcare costs make it...
07:00 , May 6, 2013 |  BioCentury  |  Finance

Panoramic view

Panoramic view Natera Inc. raised the fifth biggest venture round for a diagnostic company since the start of 2010, as investors are betting the company's Panorama Prenatal Aneuploidy Test will beat out the competition based...
07:00 , May 7, 2012 |  BC Week In Review  |  Financial News

IncellDx completes venture financing

IncellDx Inc. , Menlo Park, Calif.   Business: Diagnostic   Date completed: 4/30/12   Type: Venture financing   Raised: $4 million   Investor: Bio-Reference Laboratories Inc.   Note: IncellDx may also receive up to an...